BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
|Articles|November 16, 2020
- Pharmaceutical Executive-11-01-2020
- Volume 40
- Issue 11
Pharmaceutical Executive, November 2020 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive November 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
Synthetic Biology and the Environmentalmost 6 years ago
Measuring Pharma’s Wider Mandatealmost 6 years ago
Patients as the North Staralmost 6 years ago
Going Public During Lockdown: IPO Insights from Five Biotechnology CFOsalmost 6 years ago
A Rare-Disease Must? Building Long-Term Relationshipsalmost 6 years ago
Making Remote Work a Success Beyond COVIDalmost 6 years ago
CRISPR for Diversity, and Humanity’s, Sakealmost 6 years ago
Expediting the Cancer Treatment Pathalmost 6 years ago
Vaccine Authorization, Distribution Raise Multiple Challengesalmost 6 years ago
EU Leaders in High-Stakes Gamble on COVID ResponsesAdvertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Rebuilding Clinical Data Workflows for the AI Era
3
How Preventative Medications May Impact the Lingering Impact of COVID-19
4
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
5